Surgery Partners (SGRY) – Research Analysts’ Recent Ratings Updates

Surgery Partners (NASDAQ: SGRY) has recently received a number of price target changes and ratings updates:

• 8/21/2026 – Surgery Partners had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 8/11/2026 – Surgery Partners was given a new $18.00 price target by Raymond James Financial, Inc..
• 8/11/2026 – Surgery Partners had its “buy” rating reaffirmed by Benchmark Co..
• 8/11/2026 – Surgery Partners had its price target raised by TD Cowen from $17.00 to $19.00. They now have a “buy” rating on the stock.
• 8/11/2026 – Surgery Partners had its price target lowered by Royal Bank Of Canada from $20.00 to $19.00. They now have an “outperform” rating on the stock.
• 8/11/2026 – Surgery Partners had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $18.00 price target on the stock.
• 8/10/2026 – Surgery Partners was downgraded by Zacks Research from “strong-buy” to “hold”.

Insider Buying and Selling at Surgery Partners

In other news, Director Teresa Deluca bought 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was purchased at an average cost of $14.35 per share, with a total value of $143,500.00. Following the transaction, the director directly owned 66,843 shares in the company, valued at $959,197.05. This trade represents a 17.59% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 2.00% of the company’s stock.

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.